|
EUROSCREEN FAST adds TANGO Beta-Arrestin Assay Technology to its expanding offer for GPCR Services |
|
Brussels, Belgium, March 10, 2010 - Euroscreen SA, a global leader in the discovery of innovative drugs targeting G protein-coupled receptor (GPCRs), announced today that its business unit, Euroscreen FAST signed an agreement with Life Technologies Corporation for access to its TANGO beta-arrestin cell lines for use in drug discovery research services to be provided to Euroscreen FAST customers worldwide. Euroscreen FAST will immediately provide cell-based beta-arrestin assays as a service to customers to continue leveraging its leadership position in the GPCR custom services market. Such additional testing will extend its offer of over 700 different assays for 300 GPCRs.
|
|
Read more...
|
|
|
Euroscreen achieves Milestone in CNS Therapeutic Partnership with Cephalon |
|
Euroscreen S.A., Brussels, Belgium, January 11, 2010 - Euroscreen announced that it has completed its five-year target discovery and screening collaboration with Cephalon, Inc. In the final , two year phase of the collaboration, Euroscreen delivered optimized lead molecules on a non-disclosed, specific GPCR target triggering a milestone payment by Cephalon. Financial details were not disclosed.
|
|
Read more...
|
|
|
Identification of a Small-Molecule GPR43 Agonist |
|
|
Euroscreen announces Research Collaboration with Novartis |
|
Brussels, Belgium June 30, 2009
Euroscreen SA a leader in G Protein Coupled Receptor (GPCR) science, today announced that it signed a Research Collaboration Agreement with Novartis to discover new targets for possible application in certain disease areas. Financial terms of the deal were not disclosed.
|
|
Read more...
|
|
|
Euroscreen CCR5 Agonist program available for out-licensing |
|
A CCR5 Agonist program has been pursued at Euroscreen for 2 years, resulting in the development of a patented lead series positioned for final chemistry improvements before the declaration of a development candidate and the completion of pre-IND studies. Euroscreen's re-prioritization of programs and ressources caused the shelving of this program in October, 2008.
|
|
Read more...
|
|
|
Euroscreen expands its Drug Development Collaboration with Cephalon |
|
Euroscreen S.A., Brussels, Belgium., November 11, 2008 - Euroscreen announced that it has expanded its agreement with Cephalon, Inc. to focus on drug development for a specific target of interest to Cephalon. In 2004, Euroscreen and Cephalon initiated their collaboration to discover and develop small molecule therapeutics focused upon central nervous system diseases and targeting G-Protein Coupled Receptors (GPCR), a family of receptors that play a major role in cell signaling.
|
|
Read more...
|
|
|
Euroscreen appoints Geert Cauwenbergh and Yves Ribeill as Directors |
|
Brussels, Belgium, July 14th, 2008 - EUROSCREEN S.A. announced today that it has appointed Dr. Geert Cauwenbergh, former CEO of Barrier Therapeutics Inc. and Dr. Yves Ribeill, CEO of Scynexis, Inc., to its board of directors, adding significant, further depth and expertise to EUROSCREEN's board.
|
|
Read more...
|
|
|
Euroscreen announces Chemerin and F2L products and services license with Phoenix Pharmaceuticals Inc |
|
Brussels, Belgium, June 10th, 2008 - Euroscreen s.a. has completed a non-exclusive license agreement with Phoenix Pharmaceuticals Inc. for access to the Euroscreen's Chemerin and F2L patent rights. Financial details of this Agreement were not disclosed.
|
|
Read more...
|
|
|
Euroscreen Licenses CCR5 Patent Rights to AstraZeneca |
|
Brussels, Belgium, March 3, 2008 - Euroscreen S.A. has completed a license agreement with AstraZeneca UK Ltd, for access to its worldwide portfolio of CCR5 patent rights. Financial details of the agreement were not disclosed.
Euroscreen is the exclusive licensor of rights originally generated by ICOS, Human Genome Sciences, and Euroscreen for this combined portfolio of CCR5 patents for non-antibody therapeutic development.
|
|
Read more...
|
|
|
Euroscreen wins the opposition related to its CCR5 patent claims |
|
Brussels, Belgium 19th February 2008 Euroscreen SA today announced its success in a patent battle against Progenics Pharmaceuticals Inc.
Progenics Pharmaceuticals Inc. filed an opposition against the European patent 0 811 063 B1 owned by Euroscreen and requested to revoke the entire patent and more particularly the claims related to CCR5 antibodies.
|
|
Read more...
|
|
|
Euroscreen receives patent covering methods to identify compounds that bind to Chemerin receptor |
|
Euroscreen has been awarded a US patent for uses of Chemerin receptor and its natural ligand, Chemerin; both implicated in the control of physiological and pathological inflammatory reactions.
Brussels, Belgium 19th February 2008 – Euroscreen SA today announced the issuance of a key US patent which protects the uses of Chemerin receptor and Chemerin to discover new compounds modulating its activity, in order to develop drugs with pharmaceutical potential.
|
|
Read more...
|
|
|
News & Press Releases